PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation

E-ISSN： 1873-4286|23|11|1633-1638

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.11, 2017-05, pp. : 1633-1638

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer

Current Pharmaceutical Biotechnology, Vol. 16, Iss. 9, 2015-01 ,pp. : 804-815

Bentham Science Publishers

Access to resources Recommend Favorite

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

Clinical Cancer Drugs, Vol. 3, Iss. 1, 2016-05 ,pp. : 36-62

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 237-249

Bentham Science Publishers

Access to resources Recommend Favorite

PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress

Current Medicinal Chemistry, Vol. 17, Iss. 35, 2010-12 ,pp. : 4326-4341

Bentham Science Publishers

Access to resources Recommend Favorite